91精品国产综合久久香蕉的用户体验_震车做爰的视频|HD中文字幕在线播放,久久精品8,天天躁日日躁狠狠躁免费麻豆 ,性一交一性一交肉体

  • 新聞與活動

    學術成果

Optimal Designs for Pairwise Calculation: an Application to Free Energy Perturbation in Minimizing Prediction Variability

January 30, 2020 Pages 247-257

Pairwise-based methods such as the free energy perturbation (FEP) method have been widely deployed to compute the binding free energy differences between two similar host–guest complexes. The calculated pairwise free energy difference is either directly adopted or transformed to absolute binding free energy for molecule rank ordering. We investigated, through both analytic derivations and simulations, how the selection of pairs in the experiment could impact the overall prediction precision. Our studies showed that (1) the estimated absolute binding free energy (urn:x-wiley:01928651:media:jcc26095:jcc26095-math-0001) derived from calculated pairwise differences (ΔΔG) through weighted least squares fitting is more precise in prediction than the pairwise difference values when the number of pairs is more than the number of ligands and (2) prediction precision is influenced by both the total number of pairs and the specifically selected pairs, the latter being critically important when the number of calculated pairs is limited. Furthermore, we applied optimal experimental design in pair selection and found that the optimally selected pairs can outperform randomly selected pairs in prediction precision. In an illustrative example, we showed that, upon weighing ligand structure similarity into design optimization, the weighted optimal designs are more efficient than the literature reported designs. This work provides a new approach to assess retrospective pairwise-based prediction results, and a method to design new prospective pairwise-based experiments for molecular lead optimization. ? 2019 Wiley Periodicals, Inc.

想繼續了解更多?

聯系我們

我們期待您的留言

讓我們知道如何為您提供幫助,我們團隊將24小時內與您聯系!

姓名
電話
郵箱
國家/地區
北京市
天津市
上海市
重慶市
河北省
山西省
遼寧省
吉林省
黑龍江省
江蘇省
浙江省
安徽省
福建省
江西省
山東省
河南省
湖北省
湖南省
廣東省
海南省
四川省
貴州省
云南省
陜西省
甘肅省
青海省
臺灣省
內蒙古自治區
廣西壯族自治區
西藏自治區
寧夏回族自治區
新疆維吾爾自治區
香港特別行政區
澳門特別行政區
從事行業
小分子藥物研發
抗體藥物研發
CRO/CDMO
投融資機構
高校/研究院所/醫院
園區
生物醫藥產業
感興趣的業務
小分子藥物發現
抗體藥物發現
藥物固體形態研發
化學合成服務(含自動化合成)
實驗室自動化解決方案
所在公司
是否需要業務人員跟進?
暫不需要
驗證碼

我已閱讀并同意 晶泰科技隱私政策法律聲明